Health

Lakdawalla and Goldman. Tyler Cowen. AARP. National Pharmaceutical Council (from 2021) BIO. Adam Fein Here is a comparison of the CMS Final Rule (from 2021) vs. 2025 Trump Executive Order.

There were lots of very interesting sessions at ISPOR 2025 in Montreal. One of my favorites that I was able to attend was titled “Medicare Price Negotiation of Part B Drugs: Implications for Provider Reimbursement and Commercial Spillover“. The session was moderated by Sean Sullivan of University of Washington, with Kristi Martin from the Centers…

How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. How would MA network participation impact commercial rates? Marr et al. (2025) offers some hypotheses: On the one hand,…

Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and rebates. A paper by Lin et al. (2024) uses 2007-2023 data on drug prices from SSR Health to answer…

I’ll be at ISPOR.  Health Care Subscriptions: Who Benefits and Who Gets Left Behind? NIH bans new funding from US scientists to scientists abroad Most favored nation. CDC: RSV vaccine works.